Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof
Published in The lancet oncology (01.04.2016)
Published in The lancet oncology (01.04.2016)
Get full text
Journal Article
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Reck, Martin, Dr, Kaiser, Rolf, MD, Mellemgaard, Anders, MD, Douillard, Jean-Yves, Prof, Orlov, Sergey, Prof, Krzakowski, Maciej, Prof, von Pawel, Joachim, MD, Gottfried, Maya, MD, Bondarenko, Igor, Prof, Liao, Meilin, Prof, Gann, Claudia-Nanette, MD, Barrueco, José, PhD, Gaschler-Markefski, Birgit, PhD, Novello, Silvia, Prof
Published in The lancet oncology (01.02.2014)
Published in The lancet oncology (01.02.2014)
Get full text
Journal Article
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD
Published in The Lancet (British edition) (01.08.2015)
Published in The Lancet (British edition) (01.08.2015)
Get full text
Journal Article
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof
Published in The lancet oncology (01.01.2015)
Published in The lancet oncology (01.01.2015)
Get full text
Journal Article
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
Robertson, John F R, Prof, Bondarenko, Igor M, Prof, Trishkina, Ekaterina, PhD, Dvorkin, Mikhail, MD, Panasci, Lawrence, Prof, Manikhas, Alexey, MD, Shparyk, Yaroslav, PhD, Cardona-Huerta, Servando, PhD, Cheung, Kwok-Leung, MD, Philco-Salas, Manuel Jesus, MD, Ruiz-Borrego, Manuel, MD, Shao, Zhimin, Prof, Noguchi, Shinzaburo, Prof, Rowbottom, Jacqui, MSc, Stuart, Mary, MD, Grinsted, Lynda M, MSc, Fazal, Mehdi, MD, Ellis, Matthew J, Prof
Published in The Lancet (British edition) (17.12.2016)
Published in The Lancet (British edition) (17.12.2016)
Get full text
Journal Article